News & Updates

Older men who have had prostate-specific antigen (PSA) testing and are approaching the age limit for recommended screening appear to have a relatively low risk of developing metastatic or fatal prostate cancer, suggests a recent study.

A study conducted among Vietnamese women found that engaging in regular exercise leads to a reduction in the overall risk of breast cancer, especially the HER2-enriched subtype.

Individuals with resectable stage IA to IIIB non-small cell lung cancer (NSCLC) who plan to receive minimally invasive lung surgery may benefit from intensity-based personalized music therapy (IBP-MT) suggests the phase II Music of Lung Health II study.

The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).

In a preplanned interim analysis of the NIAGARA trial, the addition of durvalumab to neoadjuvant chemotherapy prior to radical cystectomy (RC) and durvalumab monotherapy following surgery confers a survival advantage over chemo alone for muscle-invasive bladder cancer (MIBC).

Results from the phase III KEYNOTE-522 study presented at ESMO 2024 show a statistically significant and clinically meaningful improvement in overall survival (OS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemo alone for previously untreated, high-risk, early-stage triple-negative breast cancer (TNBC).